Le Lézard
Classified in: Health, Science and technology, Business
Subject: VEN

VerImmune Inc. announces over $3M Additional Funding


WASHINGTON, Sept. 20, 2023 /PRNewswire/ -- VerImmune Inc. ("VerImmune"), an early-stage biotechnology company specializing in the development of innovative products based on a novel Virus-inspired Particle (ViPtm) technology platform, announced today the securing of an additional $3.125 million from follow-on Seed financing and a partnership milestone payment.

The follow-on financing was led by previous investor, Proxima VC, a specialist seed-to-growth healthcare venture capital firm with participation from other previous investors such as Gaingels, Mana Ventures and others. In addition to this financing, a milestone payment from Fosun Pharma USA was triggered by  the successful completion of a process development milestone.

"Receiving this additional $3.125M  financing and milestone payment resulting from our successful FDA pre-IND meeting and significant progress on CMC activities is an important step for VerImmune that further strengthens our financial position." said Joshua Wang, Founder and CEO. "We continue to be grateful to our internal team, network of advisors, existing investors, and pharmaceutical partners such as Fosun Pharma USA who believe in our technology platform and therapeutic potential of VERI-101. We intend to capitalize on this momentum and efficiently execute the next stages to enable the filing of an IND for VERI-101."

VerImmune's primary focus lies in the field of Oncology, wherein the ViP technology enables a pioneering first-in-class cancer immunotherapy approach known as Anti-tumor Immune Redirection (AIR). This innovative method harnesses the body's pre-existing immune memory from past infections or childhood vaccination to combat cancer. By taking a highly orthogonal approach, VerImmune's technology holds immense potential to revolutionize the Immuno-Oncology market, offering new treatment possibilities for patients facing limited options or resistance to current cancer therapies.

About VerImmune

VerImmune is at the forefront of innovation, dedicated to the development of a groundbreaking first-in-class cancer immunotherapy called Anti-tumor Immune Redirection (AIR). This unique strategy leverages a proprietary virus-inspired particle (ViP) technology platform to redirect pre-existing pathogenic or childhood vaccine immune memory toward tumors. VerImmune's lead immuno-oncology product candidate, VERI-101, utilizes the ViP platform to harnesses the cellular immune memory responses from prior cytomegalovirus (CMV) infection to fight cancer. Such a mechanism of action not only differentiates VerImmune within the competitive Immuno-Oncology market but also has the potential to redefine the treatment paradigm, as a stand-alone product or in combination with other immunotherapies, for patients with untreatable cancers or resistance to existing therapies. For more information, please visit http://www.verimmune.com.

SOURCE Verimmune Inc


These press releases may also interest you

19 mai 2024
Red Lobster Management LLC, along with its direct and indirect operating subsidiaries ("Red Lobster" or "the Company"), owner and operator of the Red Lobster® restaurant chain, today announced that the Company has voluntarily filed for relief under...

19 mai 2024
OKX, a leading crypto exchange and Web3 technology company, today announced a strategic partnership with Hidden Road Partners (Hidden Road), the global credit network for institutions. This partnership aims to offer a turn-key experience for Hidden...

19 mai 2024
SUNRATE, an intelligent global payment and treasury management platform today announced it has joined Mastercard Priceless Planet Coalition in support of fighting climate change through funding the restoration of 100 million trees. This announcement...

19 mai 2024
The Regional Comprehensive Economic Partnership ? a free trade agreement that has created the world's largest trading group ? is sending a strong signal in favor of open markets, fair competition and rules-based trade at a time when protectionist...

19 mai 2024
On May 16, 2024, local time in Italy, Ferretti Group Chairman Tan Xuguang hosted an on-site meeting of the Italian Ferretti company's board of directors at Milan headquarters, fully affirmed the continuous growth of the company's performance in the...

19 mai 2024
Every child deserves the best start in life. But for young families, including Millennial and Gen Z parents in Kanata and across the country, the costs of child care can add up to a second rent or mortgage payment. This makes it harder to start and...



News published on and distributed by: